Enotegrutide approved for adult weight management in China.

Pfizer China announced today that the National Medical Products Administration has officially approved the new generation cAMP-biased GLP-1 receptor agonist, semaglutide injection, for long-term weight management in adult overweight/obese patients based on controlling diet and increasing physical activity.